The Clinical Significance of O 6 -Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis

Promoter status of O -methylguanine-DNA methyltransferase ( ) has been widely established as a clinically relevant factor in glioblastoma (GBM) patients. However, in addition to varied therapy schedule, the prognosis of GBM patients is also affected by variations of age, race, primary or recurrent t...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in neurology 2018-03, Vol.9, p.127
Main Authors: Zhao, Yu-Hang, Wang, Ze-Fen, Cao, Chang-Jun, Weng, Hong, Xu, Cheng-Shi, Li, Kai, Li, Jie-Li, Lan, Jing, Zeng, Xian-Tao, Li, Zhi-Qiang
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Promoter status of O -methylguanine-DNA methyltransferase ( ) has been widely established as a clinically relevant factor in glioblastoma (GBM) patients. However, in addition to varied therapy schedule, the prognosis of GBM patients is also affected by variations of age, race, primary or recurrent tumor. This study comprehensively investigated the association between promoter status and prognosis in overall GBM patients and in different GBM subtype including new diagnosed patients, recurrent patients and elderly patients. A comprehensive search was performed using PubMed, EMBASE, Cochrane databases to identify literatures (published from January 1, 2005 to April 1, 2017) that evaluated the associations between promoter methylation and prognosis of GBM patients. Totally, 66 studies including 7,886 patients met the inclusion criteria. Overall GBM patients with a methylated status of receiving temozolomide (TMZ)-containing treatment had better overall survival (OS) and progression-free survival (PFS) [OS: hazard ratio (HR) = 0.46, 95% confidence interval (CI): 0.41-0.52,  
ISSN:1664-2295
1664-2295
DOI:10.3389/fneur.2018.00127